Clinerion's Patient Recruitment System Makes U.S. Debut
Clinerion will present its Patient Recruitment System (PRS), which allows real-time patient search for clinical trials via direct query of electronic health records.
Basel, Switzerland-based technology services company Clinerion will introduce its clinical research solutions in North America at SCOPE, the Summit for Clinical Ops Executives, and HX360, the Executive Forum for health and technology innovation (part of the HIMMS Health IT Conference).
Clinerion will present its Patient Recruitment System (PRS), which allows real-time patient search for clinical trials via direct query of electronic health records. PRS enables both electronic health record-driven protocol feasibility and patient recruitment. PRS allows trial teams to optimize protocols and to assess the possible number of suitable patients more quickly than manual screening. Patient privacy is maintained and compliant with international standards such as HIPAA, and the FDA, as patient data is never removed from the hospital premises and are de-identified before query.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
